TY - JOUR T1 - Outcome of sustained virological responders with histologically advanced chronic hepatitis C JF - Hepatology Y1 - 2010 A1 - Morgan, T.R. A1 - Ghany, M.G. A1 - Kim, H.Y. A1 - et, al KW - Adult KW - analysis KW - Antiviral Agents KW - California KW - Carcinoma KW - Carcinoma,Hepatocellular KW - Cohort Studies KW - diagnosis KW - Disease KW - Disease Progression KW - drug therapy KW - epidemiology KW - Female KW - Fibrosis KW - Follow-Up Studies KW - hepatitis KW - Hepatitis C KW - Hepatitis C,Chronic KW - Humans KW - interferon KW - Interferon Alfa-2a KW - Interferon-alpha KW - Laboratories KW - Liver KW - Liver Neoplasms KW - Liver Transplantation KW - Male KW - Middle Aged KW - Morbidity KW - Mortality KW - Multicenter Studies KW - nonresponder KW - pathology KW - Patients KW - peginterferon KW - Polyethylene Glycols KW - Prognosis KW - Prospective Studies KW - Proteins KW - Recombinant Proteins KW - Recurrence KW - Research KW - Research Support KW - Retrospective Studies KW - Ribavirin KW - Risk KW - Risk Factors KW - Severity of Illness Index KW - Survival Rate KW - SVR KW - therapeutic use KW - therapy KW - Time KW - transplantation KW - Treatment Outcome KW - United States VL - 52 SP - 833-844 IS - 3 ER -